Terrestrial Bio Raises $50 Million to Advance Therapeutic Innovations
Terrestrial Bio, a Boston-based biotech firm, has successfully raised $50 million in a Series C funding round. Known for engineering technologies that engage the human immune system, Terrestrial Bio is focused on developing a microarray patch platform to enhance the delivery of vaccines and therapeutics. This funding round was led by RA Capital, with participation from Engine Ventures, GHIC, and SiteGround.
Company Rebrand and Strategic Focus
Previously known as Vaxess Technologies, Terrestrial Bio's recent rebrand signifies a strategic pivot towards improving the delivery and accessibility of therapies. The company is initially targeting GLP-1 treatments using its proprietary microarray patch platform. This platform is designed to transform the way therapies are administered by allowing self-administration without the need for needles or refrigeration, making it more convenient for patients to use at home or on the go.
Leadership and Vision
The leadership team at Terrestrial Bio includes Kathryn Kosuda, Co-Founder and Chief Scientific Officer; Livio Valenti, Co-founder and Senior VP of Operations; and Rachel Sha, CEO. The team is committed to advancing next-generation therapies that are more accessible and user-friendly.
Use of Funds
The newly acquired funds will be directed towards establishing a new headquarters and expanding manufacturing capabilities in Boston. The company has signed a lease for a 40,000-square-foot facility in the Allston Labworks area. This facility will support the automated and scaled production of microarray patches as Terrestrial Bio prepares for late-stage clinical development and early commercialization of its lead program.
Advantages of the Microarray Patch
Terrestrial Bio's microarray patch resembles an adhesive bandage and is applied using a preloaded applicator. It delivers bioactive compounds into the skin through dissolvable tips, which participants in a recent study preferred over traditional injection devices. This innovation could lead to improved patient experience and adherence.
Future Outlook
With strong clinical and in vivo proof of concept across multiple molecules, Terrestrial Bio is poised to advance its platform further. The new facility will incorporate advanced automation, robotics, computer vision, and quality control systems, setting the stage for the company to enter the commercial market with its innovative therapies.